Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03779191
What this trial is testing

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Who this might be right for
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Instituto Nacional de Cancerologia de Mexico 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT05015010
What this trial is testing

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Gruppo Oncologico Italiano di Ricerca Clinica 33
Early research (Phase 1)Study completedNCT01121575
What this trial is testing

Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Pfizer 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06779539
What this trial is testing

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
West China Hospital 33
Testing effectiveness (Phase 2)Study completedNCT01801111
What this trial is testing

Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Who this might be right for
Non-Small-Cell Lung Carcinoma
Hoffmann-La Roche 138
Post-approval studies (Phase 4)Looking for participantsNCT05525338
What this trial is testing

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

Who this might be right for
Drug MonitoringCarcinoma, Non-Small-Cell LungLung Cancer+2 more
University Medical Center Groningen 196
Testing effectiveness (Phase 2)Looking for participantsNCT05777278
What this trial is testing

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Who this might be right for
Non-small Cell Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University 29
Early research (Phase 1)UnknownNCT02695550
What this trial is testing

Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Centaurus Biopharma Co., Ltd. 40
Large-scale testing (Phase 3)Active Not RecruitingNCT06082635
What this trial is testing

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Shenzhen TargetRx Co., Ltd. 321
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Large-scale testing (Phase 3)Study completedNCT02604342
What this trial is testing

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Hoffmann-La Roche 119
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06780839
What this trial is testing

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

Who this might be right for
NSCLC, Stage I, II, IIIA, IIIB
Peking University Cancer Hospital & Institute 70
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Testing effectiveness (Phase 2)UnknownNCT04415320
What this trial is testing

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Who this might be right for
Lung Cancer, Nonsmall CellBrain Metastases
Betta Pharmaceuticals Co., Ltd. 37
Testing effectiveness (Phase 2)Study completedNCT01685060
What this trial is testing

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 140
Not applicableLooking for participantsNCT06487078
What this trial is testing

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Who this might be right for
ALK+ Non-Small-Cell Lung Carcinoma
Pfizer 90
Early research (Phase 1)UnknownNCT03130881
What this trial is testing

Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.

Who this might be right for
Non-Small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company 60
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Large-scale testing (Phase 3)Active Not RecruitingNCT05987956
What this trial is testing

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

Who this might be right for
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair 600
Not applicableStudy completedNCT02727335
What this trial is testing

Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements

Who this might be right for
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 318
Next Page